Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 06/30/2023 | 96,250,954 | Total gross of voting rights: 96,250,954 |
| Total net* of voting rights: 96,100,982 |
* Net total = total number of voting rights attached to shares – shares without voting rights = 96,250,954 –149,972= 96,100,982
| Last Trade: | US$10.83 |
| Daily Change: | -0.16 -1.46 |
| Daily Volume: | 2,574 |
| Market Cap: | US$296.310M |
January 08, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
